Teleflex Inc. receives a $250,000 investment from Godsey & Gibb Inc.

According to the most recent disclosure made by Godsey & Gibb INC to the Securities and Exchange Commission (SEC), the company purchased a new holding in Teleflex Incorporated (NYSE: TFX) during the company's fourth quarter.

‍

The corporation paid nearly $250,000 for one thousand shares of ownership in the medical technology startup.

‍

In response to recent developments, several hedge funds have recently changed their positions in the company.

‍

Ronald Blue Trust INC spent $34,000 on Teleflex stock during the fiscal year's second quarter.

‍

General Partner, INC invested $28,000 in Teleflex stock during the final three months of 2018.

‍

This investment was worth $28,000.

‍

During the third quarter, Lazard Asset Management LLC increased its Teleflex stock holdings by 900%. Lazard Asset Management LLC has purchased an additional 180 shares of the medical technology company's stock since the beginning of the most recent quarter, bringing its total holdings to 182, valued at $36,000.

‍

These shares were previously in the possession of the company.

‍

Wipfli Financial Advisors LLC invested $55,000 in Teleflex shares during the third quarter of the current fiscal year.

‍

Last but not least, during the final three months of 2018, Romano Brothers & Company spent $69,000 to acquire an additional position in Teleflex.

‍

Institutional investors and hedge funds own most of the company's stock, accounting for 93.82% of the total.

‍

In recent years, there has been an increase in the number of research articles focusing on TFX. In a research report published on Wednesday, December 28, Stephens raised their target price for the stock from $280.00 to $295.00 and upgraded Teleflex from an "underweight" rating to an "equal weight" rating.

‍

Truist Financial assigned Teleflex a "hold" rating and reduced their target price on Teleflex stock from $260.00 to $250.00 in a research note published on Monday, February 27.

Both of these changes were made to the stock of the company.

‍

In addition, they recommended that the company "hold." Teleflex's rating at Morgan Stanley was upgraded from "equal weight" to "overweight" in a research note published on Friday, January 6.

‍

Furthermore, they raised their price target for the stock from $236.00 to $280.00. In a research note published on Friday, February 24, Raymond James upgraded Teleflex from a "outperform" rating to a "strong-buy" rating and raised their target price on the stock from $231.00 to $259.00.

‍

A research report published on Wednesday, its recommendation for Teleflex from "hold" to "buy." Seven market researchers have advised investors to purchase company stock, while six have advised investors to maintain their current holdings.

‍

According to Trade Algo, the company has received an average "Moderate Buy" recommendation, with a target price of $271.69 set.

‍

Teleflex stock rose $3.85 during the morning session on Friday, reaching a new all-time high of $245.19.

‍

There were 73,118 transactions of the stock's shares, compared to the average volume of 349,639 shares traded.

‍

The company's current price is $240.27, which is higher than its 50-day simple moving average of $229.76.

‍

The company's price-to-earnings ratio is 31.42; its price-to-earnings-to-growth ratio is 2.57; and its beta value is 0.98.

‍

It is currently valued at $11.51 billion.

‍

Teleflex Incorporated's 12-month low price was $182.65, while the company's 12-month high price was $356.72.

‍

A debt-to-equity ratio of 0.40, a current ratio of 2.43, and a quick ratio of 1.43 are displayed.

‍

Teleflex's most recent quarterly earnings report (NYSE: TFX) was made public for publication on Thursday, February 23.

‍

The firm that makes medical technology reported $3.52 in profits for the quarter, $0.08 more than the average analyst estimate of $3.44.

The company's sales for the quarter were $758 million, which was lower than the $760.29 million provided by industry professionals.

‍

The company's return on equity was 15.87%, and its net margin was 13.01%.

‍

When compared to the same quarter in the previous year, Teleflex's revenue decreased by 5%.

‍

During the same period in the previous year's financial statements, the company reported a profit of $3.60 per share. According to sell-side analysts, Teleflex Corporation will earn 13.29 cents per share in the current fiscal year.

‍

Furthermore, the company recently announced and carried out the distribution of a quarterly dividend, which occurred on March 15 of this year. Shareholders who still owned their shares as of the previous business day were eligible for a $0.34 dividend payment on Friday, March 3.

‍

According to the annualized calculation, this translates to a dividend payment of $1.36 and a yield of 0.55%.

‍

Last Thursday, March 2, was the scheduled date for dividend payments.

‍

Teleflex Corporation distributes 17.71% of its profits in the form of dividends.

Teleflex, INC's medical technology assists professionals working in the healthcare industry in their efforts to improve patient outcomes while also improving the safety of both providers and patients.

‍

‍